journal article·2021-10-20

Impact of a Desmoplastic Tumor Microenvironment for Colon Cancer Drug Sensitivity: A Study with 3D Chimeric Tumor Spheroids

Venkanagouda S. Goudar, Manohar Prasad Koduri, Yen-Nhi Ngoc Ta, Yunching Chen, Li-An Chu, Long-Sheng Lu, Fan-Gang Tseng

ACS Applied Materials & Interfaces· Volume 13· Issue 41
Publisher page

Abstract

Three-dimensional (3D) spheroid culture provides opportunities to model tumor growth closer to its natural context. The collagen network in the extracellular matrix supports autonomic tumor cell proliferation, but its presence and role in tumor spheroids remain unclear. In this research, we developed an in vitro 3D co-culture model in a microwell 3D (μ-well 3D) cell-culture array platform to mimic the tumor microenvironment (TME). The modular setup is used to characterize the paracrine signaling molecules and the role of the intraspheroidal collagen network in cancer drug resistance. The μ-well 3D platform is made up of poly(dimethylsiloxane) that contains 630 round wells for individual spheroid growth. Inside each well, the growth surface measured 500 μm in diameter and was functionalized with the amphiphilic copolymer. HCT-8 colon cancer cells and/or NIH3T3 fibroblasts were seeded in each well and incubated for up to 9 days for TME studies. It was observed that NIH3T3 cells promoted the kinetics of tumor organoid formation. The two types of cells self-organized into core–shell chimeric tumor spheroids (CTSs) with fibroblasts confined to the shell and cancer cells localized to the core. Confocal microscopy analysis indicated that a type-I collagen network developed inside the CTS along with increased TGF-β1 and α-SMA proteins. The results were correlated with a significantly increased stiffness in 3D co-cultured CTS up to 52 kPa as compared to two-dimensional (2D) co-culture. CTS was more resistant to 5-FU (IC50 = 14.0 ± 3.9 μM) and Regorafenib (IC50 = 49.8 ± 9.9 μM) compared to cells grown under the 2D condition 5-FU (IC50 = 12.2 ± 3.7 μM) and Regorafenib (IC50 = 5.9 ± 1.9 μM). Targeted collagen homeostasis with Sclerotiorin led to damaged collagen structure and disrupted the type-I collagen network within CTS. Such a treatment significantly sensitized collagen-supported CTS to 5-FU (IC50 = 4.4 ± 1.3 μM) and to Regorafenib (IC50 = 0.5 ± 0.2 μM). In summary, the efficient formation of colon cancer CTSs in a μ-well 3D culture platform allows exploration of the desmoplastic TME. The novel role of intratumor collagen quality as a drug sensitization target warrants further investigation.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: 3D Printing in Biomedical Research · Cancer Cells and Metastasis · Bone Tissue Engineering Materials

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Engineering and System Sciences, National Tsing Hua University, Hsinchu 30013, Taiwan, ROC

International Intercollegiate Ph.D. Program, National Tsing Hua University, Hsinchu 30013, Taiwan, ROC

Department of Mechanical, Materials, and Aerospace, School of Engineering, University of Liverpool, Harrison Hughes Building, Liverpool L693GH, U.K.

Institute of Biomedical Engineering, National Tsing Hua University, Hsinchu 30013, Taiwan, ROC

Department of Biomedical and Environmental Sciences, National Tsing Hua University, Hsinchu 30013, Taiwan, ROC

Brain Research Center, National Tsing Hua University, Hsinchu 30013, Taiwan, ROC

TMU Research Center of Cancer Translational Medicine, Taipei Medical University, Taipei 11031, Taiwan, ROC

Graduate Institute of Biomedical Materials and Tissue Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei 11031, Taiwan, ROC

International Ph.D. Program in Biomedical Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei 11031, Taiwan, ROC

Department of Radiation Oncology, Taipei Medical University Hospital, Taipei 11031, Taiwan, ROC

Frontier Research Center on Fundamental and Applied Sciences of Matters, National Tsing Hua University, Hsinchu 30013, Taiwan, ROC

Research Center for Applied Sciences, Academia Sinica, Taipei 11529, Taiwan, ROC

Funding

Taipei Medical University · Ministry of Education · National Health Research Institutes · National Science Council · Ministry of Science and Technology, Taiwan · Taipei Medical University Hospital

References (69)

Show source-provided references
1. 10.3322/caac.2160110.3322/caac.21601 ↗
2. 10.3389/fonc.2020.0052710.3389/fonc.2020.00527 ↗
3. 10.1186/s12964-020-0530-410.1186/s12964-020-0530-4 ↗
4. 10.3748/wjg.v20.i29.982810.3748/wjg.v20.i29.9828 ↗
5. 10.1016/j.jprot.2013.10.02010.1016/j.jprot.2013.10.020 ↗
6. 10.1038/s41388-017-0033-y10.1038/s41388-017-0033-y ↗
7. 10.1186/s13046-019-1110-610.1186/s13046-019-1110-6 ↗
8. 10.3892/ijo.2015.281610.3892/ijo.2015.2816 ↗
9. 10.1038/onc.2012.53610.1038/onc.2012.536 ↗
10. 10.1073/pnas.131841511010.1073/pnas.1318415110 ↗
11. 10.1146/annurev-bioeng-071813-10525910.1146/annurev-bioeng-071813-105259 ↗
12. 10.1073/pnas.181835711610.1073/pnas.1818357116 ↗
13. 10.1038/nature1606410.1038/nature16064 ↗
14. 10.3892/ol.2017.620910.3892/ol.2017.6209 ↗
15. 10.3892/mmr.2018.853310.3892/mmr.2018.8533 ↗
16. 10.3389/fonc.2020.0012510.3389/fonc.2020.00125 ↗
17. 10.3892/ol.2018.809710.3892/ol.2018.8097 ↗
18. 10.1080/19336918.2015.100546910.1080/19336918.2015.1005469 ↗
19. 10.1007/BF0263114310.1007/BF02631143 ↗
20. 10.1007/s40265-018-0938-y10.1007/s40265-018-0938-y ↗
21. 10.1158/0008-5472.CAN-05-224210.1158/0008-5472.CAN-05-2242 ↗
22. 10.1158/0008-5472.CAN-07-310710.1158/0008-5472.CAN-07-3107 ↗
23. 10.1093/jnci/djj39710.1093/jnci/djj397 ↗
24. 10.1073/pnas.101889210810.1073/pnas.1018892108 ↗
25. 10.1177/108705711769679510.1177/1087057117696795 ↗
26. 10.3389/fphar.2018.0000610.3389/fphar.2018.00006 ↗
27. 10.1155/2011/29060210.1155/2011/290602 ↗
28. 10.1126/science.114017110.1126/science.1140171 ↗
29. 10.2133/dmpk.DMPK-12-RG-01610.2133/dmpk.DMPK-12-RG-016 ↗
30. 10.1186/s12989-014-0056-210.1186/s12989-014-0056-2 ↗
31. 10.1016/j.ygyno.2015.04.01410.1016/j.ygyno.2015.04.014 ↗
32. 10.1039/c8bm00122g10.1039/c8bm00122g ↗
33. 10.1007/s13534-013-0105-z10.1007/s13534-013-0105-z ↗
34. 10.1039/c0lc00089b10.1039/c0lc00089b ↗
35. 10.1371/journal.pone.007334510.1371/journal.pone.0073345 ↗
36. 10.1039/c7lc00832e10.1039/c7lc00832e ↗
37. 10.1038/s41598-018-35216-710.1038/s41598-018-35216-7 ↗
38. 10.1089/ten.tec.2016.032910.1089/ten.tec.2016.0329 ↗
39. 10.1002/smll.20200425810.1002/smll.202004258 ↗
40. 10.1016/j.biomaterials.2006.06.03510.1016/j.biomaterials.2006.06.035 ↗
41. 10.1016/j.biomaterials.2011.07.02810.1016/j.biomaterials.2011.07.028 ↗
42. 10.1021/acsami.8b1071510.1021/acsami.8b10715 ↗
43. 10.1016/j.colsurfb.2009.01.00210.1016/j.colsurfb.2009.01.002 ↗
44. 10.1007/s40846-015-0029-410.1007/s40846-015-0029-4 ↗
45. 10.1021/am501390v10.1021/am501390v ↗
46. 10.1016/j.jcis.2004.11.04210.1016/j.jcis.2004.11.042 ↗
47. 10.1007/s10529-006-9133-410.1007/s10529-006-9133-4 ↗
48. 10.1038/s41598-018-20886-010.1038/s41598-018-20886-0 ↗
49. 10.1002/bit.2037210.1002/bit.20372 ↗
50. 10.1177/108705711349907110.1177/1087057113499071 ↗
51. 10.1016/j.jconrel.2016.09.00410.1016/j.jconrel.2016.09.004 ↗
52. 10.1155/2007/17527610.1155/2007/175276 ↗
53. 10.1007/s00428-018-2408-z10.1007/s00428-018-2408-z ↗
54. 10.1016/j.neo.2018.05.00810.1016/j.neo.2018.05.008 ↗
55. 10.1016/j.actbio.2018.08.00810.1016/j.actbio.2018.08.008 ↗
56. 10.1038/s41598-020-66785-110.1038/s41598-020-66785-1 ↗
57. 10.1186/1471-2407-14-51810.1186/1471-2407-14-518 ↗
58. 10.1016/j.ajpath.2011.03.01510.1016/j.ajpath.2011.03.015 ↗
59. 10.1007/s13402-020-00529-110.1007/s13402-020-00529-1 ↗
60. 10.1039/c6ra01733a10.1039/c6ra01733a ↗
61. 10.1016/j.biomaterials.2018.08.03910.1016/j.biomaterials.2018.08.039 ↗
62. 10.1021/acsnano.7b0315010.1021/acsnano.7b03150 ↗
63. 10.3390/cancers1105061210.3390/cancers11050612 ↗
64. 10.1111/cas.1340510.1111/cas.13405 ↗
65. 10.1016/j.semcancer.2013.08.00710.1016/j.semcancer.2013.08.007 ↗
66. 10.1080/15384101.2019.164206910.1080/15384101.2019.1642069 ↗
67. 10.1093/carcin/bgr10210.1093/carcin/bgr102 ↗
68. 10.1111/j.1440-1797.2006.00553.x10.1111/j.1440-1797.2006.00553.x ↗
69. 10.3390/ijms1802023610.3390/ijms18020236 ↗